As star drugs such as semaglutide and tirzepatide keep reshaping the market's understanding of GLP-1 drugs' glucose-lowering and weight-loss effects, domestic innovative pharmaceutical companies have been rushing to increase their bets on this track, and the GLP-1 market appears to already have no shortage of good drugs.
Yet alongside the continuously expanding market size, some patients still interrupt treatment due to factors such as gastrointestinal adverse reactions and treatment costs.
For type 2 diabetes patients who need long-term blood sugar control, drugs must not only be effective but also take into account tolerability, treatment convenience, and the affordability of long-term medication.
These clinical needs that have not yet been fully met are opening up new development space for GLP-1 innovative drugs with differentiated characteristics.
Recently, PEGBIO CO-B (02565) announced that its independently developed national Class 1 innovative drug, Vipenatide Injection (trade name: Paidakang®), was successfully included in the 2026 national medical insurance drug list.
Against the backdrop of increasingly abundant GLP-1 product choices and intensifying market competition, Paidakang's successful entry into the national medical insurance list not only adds a new innovative treatment option backed by medical insurance payment for patients, but also creates favorable conditions for the further release of its differentiated clinical value.
Particularly noteworthy is that Paidakang features treatment from the start without the need for dose titration, while also accumulating clinical research data on long-term glucose control and gastrointestinal tolerability, and is expected to form a recognizable competitive advantage in the massive type 2 diabetes treatment market.
The Next Round of Competition in the GLP-1 Market: Moving from Efficacy Toward Long-Term Treatment Experience
In recent years, GLP-1 drugs, with their significant glucose-lowering and weight-loss effects, have become one of the most closely watched drug categories in the global metabolic disease treatment field.
As multiple innovative products have been launched one after another, clinical treatment choices have continued to expand, and market competition has gradually extended from a sole focus on efficacy indicators to multiple dimensions including safety, tolerability, treatment convenience, and patients' long-term medication experience.
For diabetes, a chronic disease requiring long-term management, whether patients can continue treatment deserves as much attention as whether drugs can achieve effective blood sugar control.
Real-world research provides evidence for this demand.
A 2026 study involving 1,374 GLP-1 users showed that 31.7% of patients stopped treatment within 180 days; among those who discontinued, 26.8% had recorded adverse drug reactions and 14.4% had cost concerns.
Gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea are among the more closely watched issues during GLP-1 treatment, and some patients who are more sensitive to gastrointestinal reactions may therefore face challenges to treatment continuity.
This means that even though the market already has multiple GLP-1 products with outstanding efficacy, differentiated needs related to different patients' tolerance, treatment preferences, and economic burden still have important clinical significance.
From the perspective of market development trends, competition among GLP-1 drugs is not simply a ranking of efficacy.
Different patients differ in age, disease progression, physical condition, and drug tolerance, and clinical treatment also needs to take individualized needs into account.
For some patients, pursuing stronger glucose-lowering or weight-loss effects is not the only goal; achieving better treatment experience while effectively controlling blood sugar and reducing the burden of medication management also has practical value.
As the market gradually matures, products that can respond to these specific needs are expected to establish their own market positioning among different patient groups.
Without the Need for Dose Titration, Paidakang Demonstrates Differentiated Clinical Advantages
Paidakang is a long-acting GLP-1 receptor agonist independently developed by Pegbio, administered once weekly, and was approved in November 2025 for blood sugar control in adult type 2 diabetes patients.
Unlike some GLP-1 products that need to start from a lower dose and gradually increase to the therapeutic dose, Paidakang features treatment from the start without the need for dose titration, allowing patients to be dosed according to the approved regimen from the beginning of treatment and reducing the step-by-step dose adjustment process.
This feature helps simplify the clinical treatment process and also provides a more convenient treatment option for patients who need long-term medication.
In terms of gastrointestinal tolerability, Paidakang's clinical research data are also noteworthy.
Published research shows that in the Vipenatide treatment group, the incidence rates of nausea, vomiting, abdominal distension, and diarrhea were 8.0%, 5.1%, 5.1%, and 7.3%, respectively, demonstrating attractive gastrointestinal tolerability performance.
At the same time, Paidakang's pivotal clinical study provided 52-week long-term treatment data, showing that the product can achieve sustained and stable blood sugar control.
Once-weekly dosing, no need for dose titration, long-term stable glucose control, and noteworthy tolerability data together constitute Paidakang's differentiated product characteristics.
This differentiated positioning has practical significance in the current GLP-1 market.
As clinical treatment choices continue to increase, doctors can select different treatment regimens according to patients' specific conditions, and for patients who value gastrointestinal tolerability, treatment convenience, and long-term blood sugar management, Paidakang provides an innovative treatment option with different administration characteristics.
Its product competitiveness does not rely on single-dimensional comparisons with other drugs across all efficacy indicators, but rather responds to the objectively diverse needs within the diabetic patient population by balancing long-term glucose control, tolerability, and administration convenience.
Successful Medical Insurance Entry Despite Fierce Competition, Differentiated Clinical Value Ushers in a Broader Market
Against the backdrop of continuously rising competition in the domestic GLP-1 market, Paidakang's successful inclusion in the national medical insurance drug list carries noteworthy industry significance.
As innovative drugs continue to emerge, the medical insurance payment system, while improving patients' access to medication, also provides broader application conditions for treatment regimens with different clinical characteristics.
Paidakang's medical insurance access this time gives its product features, such as no need for dose titration, long-term stable glucose control, and gastrointestinal tolerability, the opportunity to benefit more type 2 diabetes patients with actual treatment needs.
Particularly noteworthy is that tolerability and economic burden are precisely important factors affecting long-term treatment for some GLP-1 users.
The differentiated characteristics Paidakang has formed in treatment convenience and tolerability, together with the improvement in payment conditions brought by this medical insurance access, are expected to create a mutually reinforcing effect.
On the one hand, the product's own clinical characteristics provide doctors with a different treatment choice; on the other hand, medical insurance payment support is expected to reduce the long-term medication burden for patients who meet payment conditions, enabling more patients to obtain innovative treatment plans suited to their own needs.
For chronic disease patients on long-term medication, this combination of clinical value and payment accessibility has practical significance.
China has a massive population of type 2 diabetes patients, and different patients have differing needs regarding drug efficacy, safety, tolerability, and treatment convenience.
Even in a market with increasingly abundant GLP-1 products, innovative drugs with clear differentiated characteristics still have market space worth watching.
Paidakang's entry into the national medical insurance list creates favorable conditions for it to further expand clinical coverage and serve different patient groups, and also allows its product characteristics to be translated into broader clinical application opportunities.
Medical Insurance Access Resonates with Real Clinical Demand, Commercialization Volume Growth Ushers in New Opportunities
For Pegbio, this medical insurance access is not only an important breakthrough in market access for its core product, but also further improves the commercialization conditions for Paidakang.
Previously, the company had reached an exclusive commercialization cooperation with Shanghai Tengrui Pharmaceutical, using professional commercialization resources to advance the product's promotion in the Chinese market.
With Paidakang's successful entry into the national medical insurance drug list, the synergy among the product's differentiated clinical characteristics, medical insurance payment support, and the commercialization promotion system is expected to gradually emerge, creating more favorable conditions for hospital access, channel coverage, and growth in clinical prescriptions.
Unlike some short-term treatment drugs, type 2 diabetes patients usually require long-term blood sugar management, and sustained, standardized treatment demand provides a long-term market foundation for related innovative drugs.
Paidakang's once-weekly, no-dose-titration administration characteristics help simplify the treatment process; its long-term glucose control and gastrointestinal tolerability data provide support for clinical application; and medical insurance access is expected to further improve the economic burden of long-term medication for patients.
As these factors gradually form a combined force, Paidakang is expected to accelerate the expansion of medical institution coverage and prescription application, driving growth in product sales scale.
From product approval and launch, to establishing a commercialization cooperation system, and then to successful inclusion in the national medical insurance drug list, Pegbio is continuously improving the commercialization layout of its first innovative drug.
The importance of this medical insurance access lies not only in obtaining payment support from the national basic medical security system, but also in more closely connecting Paidakang's differentiated clinical characteristics with real treatment needs among a massive patient population.
Against the backdrop of increasingly fierce competition in the GLP-1 market and continuously segmented patient treatment needs, Paidakang, which combines long-term glucose control effects, treatment convenience, and tolerability characteristics, is expected to gradually unleash its commercialization growth potential with a clearer market positioning.
As medical insurance policies are implemented and commercialization promotion continues to deepen, Paidakang is expected to enable more type 2 diabetes patients to obtain innovative treatment options and inject new momentum into Pegbio's future sales revenue growth.
For this innovative pharmaceutical company that is accelerating its commercialization transformation, the successful entry of its first core product into the national medical insurance drug list is both an important milestone in moving innovative R&D achievements toward broader clinical application and opens new space for the company's long-term development in China's metabolic disease treatment market.
Comments